Home / NAD+ explained: biochemistry, precursors, testing and the human evidence
NAD+ explained: biochemistry, precursors, testing and the human evidence
Prepared by: Research Desk. Sources are linked for verification.
NAD+ has become shorthand for “cellular energy” in longevity marketing. The science underneath is real and important. NAD+ is one of the most central molecules in metabolism. But between “NAD+ declines with age” and “this capsule will make you younger” lies a long chain of assumptions, and most of them haven’t been tested in people. This guide works through that chain one link at a time.
Contents
Part 1: What NAD+ actually does
Nicotinamide adenine dinucleotide exists in two forms: oxidised (NAD+) and reduced (NADH). It has two quite different jobs.
Job 1: electron carrier
In energy metabolism, NAD+ accepts electrons from the breakdown of glucose and fats and becomes NADH. NADH then delivers those electrons to the mitochondria, where they drive ATP production. In this role NAD+ is recycled, not consumed. That’s why it’s sometimes described as the cell’s hydrogen carrier for redox reactions [1].
Job 2: substrate that gets used up
NAD+ is also a raw material for several enzyme families. These enzymes consume it:
PARPs (poly-ADP-ribose polymerases) help repair DNA damage.
Sirtuins are enzymes that regulate gene expression and metabolism and are linked to the effects of calorie restriction in animal studies.
CD38 is an enzyme, abundant on immune cells, that breaks down NAD+.
This second job is the basis of the aging hypothesis. More DNA damage and inflammation mean more consumption, and lower NAD+ levels may limit repair and metabolism.
Part 2: Does NAD+ really decline with age?
In animals, consistently yes. In humans the evidence is real but patchier than marketing implies.
49
people
A study of human skin samples from 49 people aged from infancy to 77 found strong negative correlations between age and tissue NAD+ levels, in both men and women. It also found rising PARP activity with age in men [2]. That study supports the idea that NAD+ is consumed faster with age, at least in skin.
Method caveats: Correlations in one tissue don’t tell us about every tissue. NAD+ levels also vary with time of day, food intake and exercise [1], so a single measurement is a snapshot.
Part 3: How the body makes NAD+
The body has three main production routes:
De novo pathway: built from the amino acid tryptophan.
Preiss-Handler pathway: starts from nicotinic acid (niacin).
Salvage pathway: recycles nicotinamide, the leftover after NAD+ is consumed. This is the main route in most tissues.
NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are intermediates that enter near the end of the salvage pathway. That’s why they’re promoted as efficient precursors.
A 2026 twist: the gut may be doing the work
65
healthy adults
14
days
In a randomized, placebo-controlled study of 65 healthy adults, 14 days of NR or NMN raised circulating NAD+ by similar amounts. Nicotinamide did not [3]. Experiments using human gut bacteria found that NR and NMN were converted into nicotinic acid, which then fed the Preiss-Handler pathway [3]. The authors propose a gut-dependent model of how these precursors work [3].
Why it matters: The “NMN goes straight into cells” story may be too simple. It also means differences in gut bacteria could affect who responds. This study was funded and run by Nestlé researchers [3]. That’s worth knowing, though it doesn’t by itself undermine the findings.
Part 4: NMN vs NR
NR
NMN
Structure
Nicotinamide + ribose
NR + a phosphate group
Raises blood NAD+ in humans?
Yes [3][4]
Yes [3]
Notable human RCT
2×6-week crossover in healthy middle-aged and older adults: well tolerated, raised NAD+ metabolism [4]
10-week trial in postmenopausal women with prediabetes: improved muscle insulin sensitivity [5]
U.S. status
Dietary supplement
Dietary supplement, after FDA’s September 2025 revision (see our legal explainer)
Bottom line: Head-to-head, the 2026 study found they raised circulating NAD+ comparably [3]. There’s no good human evidence that one is clearly superior on health outcomes.
Part 5: What randomized human trials show
Target engagement: consistent
human intervention studies
randomized
A 2026 systematic review identified 33 human intervention studies of NAD-related compounds, 28 of them randomized. It found that oral NR and NMN consistently raised NAD-related metabolites in blood or cells and were generally well tolerated over weeks to months [6].
Clinical outcomes: inconsistent
The same review found that effects on functional, metabolic, vascular and other healthspan-relevant outcomes were “heterogeneous and often null or endpoint-specific” [6]. Two examples:
NR in healthy older adults. In the 2018 crossover trial, NR was well tolerated and raised NAD+ metabolism. The authors suggested blood pressure and arterial stiffness as outcomes for future trials, rather than reporting a proven effect [4].
NMN in women with prediabetes. A 10-week randomized trial found increased muscle insulin sensitivity, insulin signalling and remodelling [5]. That’s a meaningful result. But it was in a specific group (overweight or obese postmenopausal women with prediabetes), and the abstract reports muscle insulin outcomes rather than broad health outcomes. It isn’t a general anti-aging result. Some authors disclosed NMN-related patent interests [5].
Lifespan: untested
No human trial has tested whether NAD+ precursors extend lifespan. Animal results are encouraging [1], but they can’t simply be transferred to people.
Part 6: IV NAD+
IV NAD+ drips are widely marketed by wellness businesses. The evidence base is thin. The 2026 systematic review found no eligible outcome trials of intravenous or intramuscular NAD+ for anti-aging or wellness. It identified only a small IV pharmacokinetic pilot as context [6].
Method question for any provider’s claim: what outcome, measured how, in which trial? A report that people “feel better” is an uncontrolled observation, not evidence.
Part 7: How NAD+ is measured
This is our lab-methods specialty, and it’s where consumer testing often falls short.
What gets measured
Whole blood NAD+. Most consumer tests use a finger-prick sample. Red blood cells hold most of the NAD+ in blood.
Plasma metabolites. NAD+ breakdown products and precursors.
PBMCs. Immune cells, used in research.
Tissue biopsies, such as muscle or skin. These are the most direct measure, but invasive.
Why numbers aren’t comparable
Different sample types give different results, so whole blood and muscle tissue can’t be compared directly.
Different methods. Enzymatic cycling assays and LC-MS (mass spectrometry) differ in specificity.
Pre-analytical handling. NAD+ is unstable, so how fast a sample is processed matters.
Biological variability. Time of day, recent meals and exercise all shift levels [1].
Questions to ask about an NAD+ test
What sample type and assay method are used?
Is the lab CLIA-certified (for U.S. tests)?
What reference range is used, and from what population?
Is there evidence that changing the number improves any health outcome? (Currently, the answer is no.)
Part 8: Safety notes
Oral NR and NMN were generally well tolerated in trials lasting weeks to months [6]. Long-term safety over years isn’t established. Theoretical concerns discussed in the research literature include effects on cancer cell metabolism, since tumours also use NAD+. These are unresolved.
Summary: the chain of evidence
Link
Evidence strength
NAD+ is essential for metabolism and DNA repair
Very strong [1]
NAD+ declines with age in human tissue
Moderate (e.g. skin) [2]
NR and NMN raise NAD+ in human blood
Strong [3][4][6]
Raising NAD+ improves health outcomes in humans
Weak to inconsistent [5][6]
IV NAD+ improves wellness outcomes
No outcome trials [6]
NAD+ precursors extend human lifespan
Untested
Our five-question method for reading any NAD+ study
We apply the same checklist to every new paper we cover:
Population. Healthy young adults, older adults, or a disease group? The NMN insulin-sensitivity result came from postmenopausal women with prediabetes who were overweight or obese [5]. It doesn’t automatically apply to anyone else.
Comparator. Was there a placebo, and was the study blinded? The 2026 three-precursor comparison was randomized and placebo-controlled but open-label [3].
Outcome type. Is the main result a biomarker (blood NAD+) or a clinical outcome (function, disease, symptoms)? Most positive results so far are biomarker results [6].
Duration. Weeks, months or years? Most trials run for weeks to a few months [6].
Funding and conflicts. Who paid, and does anyone hold patents? Check the disclosure section. Several key studies have industry funding or patent interests [3][5].
Quick FAQ
Is NMN better than NR? In the only head-to-head human comparison we cite, both raised circulating NAD+ comparably over 14 days [3].
Can an NAD+ test show whether a supplement is needed? No validated threshold exists for that. Numbers vary by sample type, method and time of day [1].
Is niacin an NAD+ precursor too? Yes. Nicotinic acid feeds the Preiss-Handler pathway [3]. At higher amounts it can cause flushing and other effects.
Last updated: 18 October 2026.
Not medical advice. This page reports published research and regulatory records for information only.